NEW YORK, Jan 9 – GPC Biotech has signed on to a proteomics and genomics deal with Boehringer Ingelheim pharmaceuticals, in which GPC will identify targets and pathways associated with human papillomavirus, GPC announced Tuesday.
In this project, GPC Biotech is using OliCode molecular cloning technology, PathCode yeast two-hybrid protein-protein interaction identification technology, and its bioinformatics applications.
Based on these targets, Boehringer Ingelheim hopes to develop new treatments and preventative therapies for HPV-related illnesses.
Boehringer Ingelheim is paying GPC Biotech license fees, milestone payments for clinical development, and royalties on sales of any products it develops using GPC Biotech’s targets.
Boehringer Ingelheim will also provide research funding for research. GPC estimated that total payments from Boehringer Ingelheim could add up to $30 million.
This deal follows an earlier collaboration, in which GPC Biotech defined gene expression profiles for Boehringer Ingleheim using its ExpressCode technology and provided information about target function.
GPC has also formed similar partnerships with Aventis, Bayer, Du Pont, Altana, Cell Genesys, Maxim Pharmaceuticals, Evotec Biosystems, Morphosys, and Karo Bio.